Health Care & Life Sciences » Pharmaceuticals | Corium International Inc.

Corium International Inc. | Balance Sheet

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
13,581.00
36,395.00
72,218.00
39,833.00
57,466.00
Total Accounts Receivable
4,624.00
5,553.00
5,273.00
4,682.00
4,810.00
Inventories
4,508.00
2,592.00
2,902.00
2,424.00
2,300.00
Other Current Assets
1,038.00
1,292.00
1,367.00
1,341.00
982.00
Total Current Assets
23,751.00
45,832.00
81,760.00
48,280.00
65,558.00
Net Property, Plant & Equipment
12,622.00
12,658.00
11,593.00
11,147.00
12,176.00
Total Investments and Advances
-
-
-
666.00
-
Long-Term Note Receivable
100.00
-
-
-
-
Intangible Assets
6,647.00
6,683.00
6,837.00
7,057.00
7,117.00
Other Assets
902.00
571.00
554.00
-
-
Total Assets
44,022.00
65,744.00
100,744.00
67,150.00
84,851.00
ST Debt & Current Portion LT Debt
5,359.00
867.00
877.00
149.00
13,697.00
Accounts Payable
2,748.00
2,512.00
3,952.00
2,737.00
3,978.00
Other Current Liabilities
7,050.00
5,083.00
4,985.00
5,086.00
6,626.00
Total Current Liabilities
15,157.00
8,462.00
9,814.00
7,972.00
24,301.00
Long-Term Debt
68,374.00
39,046.00
49,879.00
50,966.00
39,027.00
Provision for Risks & Charges
-
-
-
-
1,811.00
Other Liabilities
19,106.00
6,436.00
5,729.00
5,359.00
3,500.00
Total Liabilities
102,637.00
53,944.00
65,422.00
64,297.00
68,639.00
Common Equity (Total)
119,100.00
11,800.00
35,322.00
2,853.00
16,212.00
Total Shareholders' Equity
58,615.00
11,800.00
35,322.00
2,853.00
16,212.00
Total Equity
58,615.00
11,800.00
35,322.00
2,853.00
16,212.00
Liabilities & Shareholders' Equity
44,022.00
65,744.00
100,744.00
67,150.00
84,851.00
Preferred Stock (Carrying Value)
60,485.00
-
-
-
-

About Corium International

View Profile
Address
235 Constitution Drive
Menlo Park California 94025
United States
Employees -
Website http://www.coriumgroup.com
Updated 09/14/2018
Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. The firm offers its products under the brands Corplex and MicroCor.